Lipocine Inc. Files 8-K

Ticker: LPCN · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1535955

Lipocine Inc. 8-K Filing Summary
FieldDetail
CompanyLipocine Inc. (LPCN)
Form Type8-K
Filed DateJun 10, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Lipocine filed an 8-K on June 8th, check for updates.

AI Summary

Lipocine Inc. filed an 8-K on June 10, 2024, reporting other events and financial statements/exhibits as of June 8, 2024. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates that Lipocine Inc. has submitted a report to the SEC, which may contain important updates for investors regarding company events or financial status.

Risk Assessment

Risk Level: low — The filing is a standard procedural report with no immediate negative or positive financial implications disclosed in the provided text.

Key Players & Entities

  • Lipocine Inc. (company) — Registrant
  • June 8, 2024 (date) — Date of Earliest Event Reported
  • June 10, 2024 (date) — Filing Date
  • 675 Arapeen Drive, Suite 202 (address) — Principal Executive Offices
  • Salt Lake City, Utah 84108 (address) — Principal Executive Offices

FAQ

What specific events are being reported in this 8-K filing?

The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not specify the details of these events.

When was the earliest event reported in this filing?

The earliest event reported was on June 8, 2024.

What is the filing date of this 8-K report?

The filing was made on June 10, 2024.

What is the principal executive office address for Lipocine Inc.?

The principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.

What is the SEC file number for Lipocine Inc.?

The SEC file number for Lipocine Inc. is 001-36357.

Filing Stats: 521 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-06-10 09:00:30

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: June 10, 2024 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.